NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings data on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.04. The medical instruments supplier had revenue of $66 million for the quarter, compared to analysts' expectations of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The business's revenue was up 3.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, January 7th 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics will be holding an earnings conference call on Tuesday, January 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AngioDynamics updated its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 equities research analysts have issued 12-month price objectives for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they expect AngioDynamics' share price to reach $22.00 in the next year. This suggests a possible upside of 41.6% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Headlines about ANGO stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 992,900 shares, an increase of 17.8% from the November 14th total of 843,100 shares. Based on an average daily volume of 299,700 shares, the days-to-cover ratio is currently 3.3 days. Currently, 2.7% of the shares of the company are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), FireEye (FEYE), Intel (INTC), Mattel (MAT), General Electric (GE), Bank of America (BAC), Centurylink (CTL), Hanesbrands (HBI), Marathon Oil (MRO) and Century Aluminum (CENX).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.69%), Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Granahan Investment Management Inc. MA (1.11%), Systematic Financial Management LP (1.09%) and Foundry Partners LLC (0.65%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Man Group plc, Tributary Capital Management LLC, Barclays PLC, Foundry Partners LLC, State Street Corp and Keybank National Association OH. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mackay Shields LLC, Assenagon Asset Management S.A., Boston Advisors LLC, Systematic Financial Management LP, Granahan Investment Management Inc. MA, Tibra Equities Europe Ltd and Meeder Asset Management Inc.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.54.

AngioDynamics has a market capitalization of $584.61 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]